EXD2

Across TCGA pan-cancer cohorts, EXD2 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of EXD2’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where EXD2 RNA is repressed in tumor relative to normal tissue. In most cancer types EXD2 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, KIRC, and CHOL are the cancer types where EXD2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EXD2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.821	<.001	10	view →
KIRC	Male	II,III,IV	−0.517	<.001	9	view →
CHOL	Male	All	+1.835	<.001	5	view →
LIHC	Female	II,III,IV	+0.540	.001	5	view →
ESCA	All	II,III,IV	+0.379	.044	2	view →
PRAD	All	All	+0.190	.032	2	view →
LUSC	All	III,IV	−0.388	.019	1	view →
KIRP	All	II,III,IV	+0.388	.040	1	view →
KICH	All	All	−0.294	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

EXD2–THCA

Open the THCA breakdown →